Aarti Drugs Ltd Q1 FY26 – ₹591 Cr Sales, ₹54 Cr PAT, FDA Alert Lifted but MPCB Leak Adds Masala
1. At a Glance
Aarti Drugs just dropped Q1 FY26 results: Sales ₹591 Cr, Profit ₹54 Cr, YoY profit up 62%. FDA import alert gone, new plant commissioned, but Maharashtra Pollution Control Board (MPCB) told them to shut a unit after an HCl leak. Stock trades at P/E ~25 — basically, the market is pricing it like a healthy tablet, but it still tastes like Crocin without water.
2. Introduction
Born in 1984, part of the Aarti Group (the ₹1 bn conglomerate, not the one that sings bhajans), Aarti Drugs has become India’s pharmacy backend. It makes APIs that your doctor prescribes without telling you — Metformin, Ciprofloxacin, Ofloxacin, Nimesulide, Tinidazole, and the gang.
The company is:
Largest producer of fluoroquinolones worldwide (aka antibiotics your doctor prescribes after diagnosing you with “thoda infection hai”).
A global supplier in 100+ countries (Brazil to Switzerland, even Pakistan buys from them — so “Made in India” is curing their fever too).
Backward integrated: meaning they manufacture the raw materials to their raw materials. That’s like cooking your own masala before making biryani.
But despite such pharma bragging rights, sales growth has been flatter than hostel chapati: just 5.7% in 5 years. Why? API prices swinging, regulatory issues, and occasional “government tax demand” like ₹230 Cr IGST case.
3. Business Model – WTF Do They Even Do?
1) API (81%) – The real bread & butter. 50+ molecules across antibiotics, anti-diabetic, anti-fungal, etc. Demand cycles depend on how many Indians get fever every monsoon. 9 manufacturing units, 46,000 TPA capacity.
2) Formulations (11%) – Tablets & capsules via Pinnacle Life Science (capacity 3 Bn tablets). But revenue down 28% YoY — probably because generic competition is deadlier than bacteria.
3) Specialty Chemicals & Intermediates (8%) – Benzene sulfonyl chloride, chlorosulphonation derivatives. These intermediates are basically “prep material” for APIs. Demand steady, but MPCB just shut one Tarapur chlorosulfonation section post acid leak. Safety standards = “lab coat aur bhagwan bharose.”
4. Financials Overview
Metric
Latest Qtr (Q1 FY26)
YoY Qtr (Q1 FY25)
Prev Qtr (Q4 FY25)
YoY %
QoQ %
Revenue
591
555
677
6.3%
-12.7%
EBITDA
74
65
93
13.8%
-20.4%
PAT
53.9
33
63
62.2%
-14.5%
EPS (₹)
5.86
3.62
6.84
61.9%
-14.3%
Commentary: YoY looks healthy, QoQ looks like crash diet. Annualised EPS ~₹23 → At CMP ₹508, P/E ~22. The official 24.7 P/E is basically the same. Industry P/E ~34, so this is “generic version” pricing.
5. Valuation – Fair Value Range
Method 1: P/E
EPS FY25 = ₹20.5
Assign 18x–25x → Fair value ₹370–₹510
Method 2: EV/EBITDA
EV ~₹5,274 Cr
EBITDA FY25 ~₹296 Cr → EV/EBITDA = 17.8x
Industry fair 12–16x → Value range ₹3,550–₹4,740 Cr EV → ₹385–₹515/share
